Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study.
Rambaldi A, Iurlo A, Vannucchi AM, Noble R, von Bubnoff N, Guarini A, Martino B, Pezzutto A, Carli G, De Muro M, Luciani S, McMullin MF, Cambier N, Marolleau JP, Mesa RA, Tibes R, Pancrazzi A, Gesullo F, Bettica P, Manzoni S, Di Tollo S. Rambaldi A, et al. Among authors: de muro m. Leukemia. 2020 Aug;34(8):2234-2237. doi: 10.1038/s41375-020-0735-y. Epub 2020 Feb 11. Leukemia. 2020. PMID: 32047238 Free PMC article. Clinical Trial. No abstract available.
Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up.
Di Veroli A, Buccisano F, Andriani A, Montanaro M, Latagliata R, Santoro C, Breccia M, Spirito F, Cedrone M, Anaclerico B, Leonetti Crescenzi S, Porrini R, De Muro M, Avvisati G, Tafuri A, Cimino G, Spadea A. Di Veroli A, et al. Among authors: de muro m. Leuk Res. 2018 Jun;69:18-23. doi: 10.1016/j.leukres.2018.03.016. Epub 2018 Mar 31. Leuk Res. 2018. PMID: 29625320 No abstract available.
Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program.
Rambaldi A, Iurlo A, Vannucchi AM, Martino B, Guarini A, Ruggeri M, von Bubnoff N, De Muro M, McMullin MF, Luciani S, Martinelli V, Nogai A, Rosti V, Ricco A, Bettica P, Manzoni S, Di Tollo S. Rambaldi A, et al. Among authors: de muro m. Blood Cancer J. 2021 Mar 6;11(3):53. doi: 10.1038/s41408-021-00445-z. Blood Cancer J. 2021. PMID: 33677466 Free PMC article. Clinical Trial.
Deferasirox in the treatment of iron overload during myeloproliferative neoplasms in fibrotic phase: does ferritin decrement matter?
Di Veroli A, Campagna A, De Muro M, Maurillo L, Trawinska MM, LeonettiCrescenzi S, Petriccione L, Romano A, D'Addosio A, Cenfra A, Montanaro M, Felici S, Andriani A, Carmosino I, Niscola P, Montefusco E, Breccia M, Latagliata R. Di Veroli A, et al. Among authors: de muro m. Leuk Res. 2019 Jan;76:65-69. doi: 10.1016/j.leukres.2018.11.012. Epub 2018 Dec 4. Leuk Res. 2019. PMID: 30578958
Sequential occurrence of chronic myeloproliferative and lymphoproliferative neoplasms: a collaborative retrospective study by pH-negative MPN latial group.
Breccia M, Petriccione L, Tatarelli C, De Muro M, Trawinska MM, Santopietro M, Spadea A, Di Veroli A, Scalzulli E, Paciaroni K, Tafuri A, Latagliata R, Andriani A, Di Napoli A. Breccia M, et al. Among authors: de muro m. Leuk Lymphoma. 2022 Nov;63(11):2751-2753. doi: 10.1080/10428194.2022.2092859. Epub 2022 Jun 25. Leuk Lymphoma. 2022. PMID: 35758305 No abstract available.
Impact on mental health, disease management, and socioeconomic modifications in hematological patients during the COVID-19 pandemic in Italy.
De Muro M, Janssen AJ, Amadori S, de Fabritiis P, Sabatino D, Niscola P, Torti L, Trawinska MM, Tesei C, Bombaci F, Tarricone M, Bocchia M, Fava C, Galimberti S, Iurlo A, Luciano L, Abruzzese E. De Muro M, et al. Ther Adv Hematol. 2023 Sep 6;14:20406207231190683. doi: 10.1177/20406207231190683. eCollection 2023. Ther Adv Hematol. 2023. PMID: 37693118 Free PMC article.
Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant.
Spina F, Montefusco V, Crippa C, Citro A, Sammassimo S, Olivero B, Gentili S, Galli M, Guglielmelli T, Rossi D, Falcone AP, Grasso M, Patriarca F, De Muro M, Corradini P. Spina F, et al. Among authors: de muro m. Leuk Lymphoma. 2011 Jul;52(7):1262-70. doi: 10.3109/10428194.2011.564695. Epub 2011 May 3. Leuk Lymphoma. 2011. PMID: 21534872
Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug.
Latagliata R, Spadea A, Cedrone M, Di Giandomenico J, De Muro M, Villivà N, Breccia M, Anaclerico B, Porrini R, Spirito F, Rago A, Avvisati G, Alimena G, Montanaro M, Andriani A; Gruppo Laziale SMPC Ph1 neg. Latagliata R, et al. Among authors: de muro m. Cancer. 2012 Jan 15;118(2):404-9. doi: 10.1002/cncr.26194. Epub 2011 Jun 20. Cancer. 2012. PMID: 21692060 Free article.
Evolution of bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma and Waldenstrom's macroglobulinemia: a retrospective multicentric study.
Andriani A, Petrucci MT, Caravita T, Montanaro M, Villivà N, Levi A, Siniscalchi A, Bongarzoni V, Pisani F, De Muro M, Coppetelli U, Avvisati G, Zullo A, Agrillo A, Gaglioti D. Andriani A, et al. Among authors: de muro m. Blood Cancer J. 2012 Mar;2(3):e62. doi: 10.1038/bcj.2012.9. Epub 2012 Mar 23. Blood Cancer J. 2012. PMID: 22829257 Free PMC article.
Thrombosis and survival in essential thrombocythemia: a regional study of 1,144 patients.
Montanaro M, Latagliata R, Cedrone M, Spadea A, Rago A, Di Giandomenico J, Spirito F, Porrini R, De Muro M, Leonetti SC, Villivà N, De Gregoris C, Breccia M, Montefusco E, Santoro C, Cimino G, Majolino I, Mazzucconi MG, Alimena G, Andriani A. Montanaro M, et al. Among authors: de gregoris c, de muro m. Am J Hematol. 2014 May;89(5):542-6. doi: 10.1002/ajh.23685. Epub 2014 Feb 21. Am J Hematol. 2014. PMID: 24481665 Free article.
26 results